OMEPRAZOLE AS AN ADJUVANT TO ANTIMICROBIAL THERAPY FOR ERADICATION OF HELICOBACTER-PYLORI INFECTION

被引:11
作者
GRAHAM, DY
RAMIREZ, FC
LEW, GM
KLEIN, PD
MALATY, HM
GENTA, RM
机构
[1] BAYLOR COLL MED, DEPT MED, HOUSTON, TX 77030 USA
[2] BAYLOR COLL MED, DEPT PEDIAT, HOUSTON, TX 77030 USA
[3] BAYLOR COLL MED, DEPT PATHOL, HOUSTON, TX 77030 USA
[4] BAYLOR COLL MED, DIV MOLEC VIROL, HOUSTON, TX 77030 USA
[5] BAYLOR COLL MED, USDA ARS, CHILDRENS NUTR RES CTR, HOUSTON, TX 77030 USA
来源
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL | 1994年 / 55卷 / 03期
关键词
D O I
10.1016/S0011-393X(05)80165-1
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The first therapies to reliably eradicate Helicobacter pylori used combinations of bismuth, metronidazole, and tetracycline or amoxicillin. The increasing frequency of metronidazole resistance, however, has limited the effectiveness of the original combination therapies. As with the use of bismuth compounds, proton pump inhibitors can be used to kill H pylori but are themselves insufficient to eradicate the infection. Proton pump inhibitors markedly increase gastric pH. Because this action may make antimicrobials more effective, we evaluated omeprazole as an adjuvant to antimicrobial therapy. We tested omeprazole 20 mg TID for 7 days as an adjuvant to oral clarithromycin 500 mg TID or gentamicin 20 mg TID (each was given for the final 5 days of the 7-day treatment course). Eradication was defined as the absence of evidence of H pylori 4 or more weeks after cessation of therapy. Eleven patients with active peptic ulcer disease were treated with omeprazole/clarithromycin; the eradication rate was 64%. Six healthy H pylori-infected volunteers were treated with omeprazole/gentamicin; no eradication was achieved. Omeprazole appears to be a useful adjuvant to some therapies but the results cannot be predicted. Combination therapy with omeprazole and clarithromycin warrants further study.
引用
收藏
页码:213 / 219
页数:7
相关论文
共 42 条
[21]  
HU FL, 1988, CHUNG HUA NEI KO TSA, V27, P721
[22]   EFFECT OF OMEPRAZOLE ON DUODENAL ULCER-ASSOCIATED ANTRAL GASTRITIS AND HELICOBACTER-PYLORI [J].
HUI, WM ;
LAM, SK ;
HO, J ;
LAI, CL ;
LOK, ASF ;
NG, MMT ;
LAU, WY ;
BRANICKI, FJ .
DIGESTIVE DISEASES AND SCIENCES, 1991, 36 (05) :577-582
[23]   LANSOPRAZOLE, A NOVEL BENZIMIDAZOLE PROTON PUMP INHIBITOR, AND ITS RELATED-COMPOUNDS HAVE SELECTIVE ACTIVITY AGAINST HELICOBACTER-PYLORI [J].
IWAHI, T ;
SATOH, H ;
NAKAO, M ;
IWASAKI, T ;
YAMAZAKI, T ;
KUBO, K ;
TAMURA, T ;
IMADA, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (03) :490-496
[24]   CLARITHROMYCIN AND OMEPRAZOLE FOR HELICOBACTER-PYLORI [J].
LOGAN, RPH ;
GUMMETT, PA ;
HEGARTY, BT ;
WALKER, MM ;
BARON, JH ;
MISIEWICZ, JJ .
LANCET, 1992, 340 (8813) :239-239
[25]   PYLORIC CAMPYLOBACTER INFECTION AND GASTRODUODENAL DISEASE [J].
MARSHALL, BJ ;
MCGECHIE, DB ;
ROGERS, PA ;
GLANCY, RJ .
MEDICAL JOURNAL OF AUSTRALIA, 1985, 142 (08) :439-444
[26]   SUSCEPTIBILITY OF CLINICAL ISOLATES OF CAMPYLOBACTER-PYLORI TO 21 ANTIMICROBIAL AGENTS [J].
MCNULTY, CA ;
DENT, JC .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1988, 7 (04) :566-569
[27]   SUSCEPTIBILITY OF CLINICAL ISOLATES OF CAMPYLOBACTER-PYLORIDIS TO 11 ANTIMICROBIAL AGENTS [J].
MCNULTY, CAM ;
DENT, J ;
WISE, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1985, 28 (06) :837-838
[28]   ACTIVITY OF LANSOPRAZOLE AGAINST HELICOBACTER-PYLORI [J].
MEGRAUD, F ;
BOYANOVA, L ;
LAMOULIATTE, H .
LANCET, 1991, 337 (8755) :1486-1486
[29]   THE SUSCEPTIBILITY OF CAMPYLOBACTER-PYLORI TO ANTIULCER AGENTS AND ANTIBIOTICS [J].
NAGATE, T ;
NUMATA, K ;
HANADA, K ;
KONDO, I .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 1990, 12 :S135-S138
[30]   ADJUVANT ANTIBIOTIC-THERAPY IN DUODENAL-ULCERS TREATED WITH COLLOIDAL BISMUTH SUBCITRATE [J].
ORIORDAN, T ;
MATHAI, E ;
TOBIN, E ;
MCKENNA, D ;
KEANE, C ;
SWEENEY, E ;
OMORAIN, C .
GUT, 1990, 31 (09) :999-1002